ALX Oncology Holdings Inc. (NASDAQ:ALXO – Get Free Report) was the recipient of a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 9,980,000 shares, an increase of 7.5% from the August 15th total of 9,280,000 shares. Based on an average daily volume of 1,280,000 shares, the short-interest ratio is presently 7.8 days. Currently, 33.0% of the company’s stock are short sold.
ALX Oncology Stock Down 1.8 %
ALX Oncology stock opened at $2.14 on Thursday. ALX Oncology has a fifty-two week low of $1.88 and a fifty-two week high of $17.83. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.39 and a current ratio of 4.39. The company has a market capitalization of $111.49 million, a P/E ratio of -0.58 and a beta of 1.01. The stock has a 50-day simple moving average of $3.66 and a 200-day simple moving average of $8.92.
ALX Oncology (NASDAQ:ALXO – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.01. Equities research analysts expect that ALX Oncology will post -3.04 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Read Our Latest Report on ALXO
Insider Activity at ALX Oncology
In related news, insider Jaume Pons sold 20,000 shares of ALX Oncology stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $7.90, for a total value of $158,000.00. Following the completion of the transaction, the insider now directly owns 593,447 shares in the company, valued at $4,688,231.30. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last three months, insiders sold 28,398 shares of company stock worth $200,043. Company insiders own 33.40% of the company’s stock.
Hedge Funds Weigh In On ALX Oncology
Institutional investors have recently added to or reduced their stakes in the stock. CANADA LIFE ASSURANCE Co acquired a new position in ALX Oncology in the 1st quarter valued at about $27,000. EntryPoint Capital LLC acquired a new position in ALX Oncology in the 1st quarter valued at about $32,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in ALX Oncology by 394.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after acquiring an additional 5,200 shares during the period. China Universal Asset Management Co. Ltd. increased its position in ALX Oncology by 66.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,587 shares of the company’s stock valued at $107,000 after acquiring an additional 3,825 shares during the period. Finally, Hsbc Holdings PLC acquired a new position in ALX Oncology in the 2nd quarter valued at about $63,000. Institutional investors and hedge funds own 97.97% of the company’s stock.
ALX Oncology Company Profile
ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.
Further Reading
- Five stocks we like better than ALX Oncology
- How to Buy Cheap Stocks Step by Step
- How Much Can You Make in Stocks in One Month?
- What Is WallStreetBets and What Stocks Are They Targeting?
- This Is the Top Large-Cap Stock Insiders Are Buying
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.